Baxalta in talks to buy drugmaker to bolster independence
Baxalta is working with bankers on the acquisition of a U.S.-based hematology-oncology specialist valued at about $2 billion, said the people, who asked not to be identified because the information is private. ... Shire is interested in Baxalta to ...
Crain's Chicago Business - Fri, 28 Aug 2015 10:15

Baxalta Said in Talks to Buy Ariad to Boost Cancer Offerings
Bloomberg - Fri, 28 Aug 2015 09:38



Biomarkers in Hematological Malignancies: A Review of Molecular Testing in ...
Background: Molecular interrogation of genetic information has transformed our understanding of disease and is now routinely integrated into the workup and monitoring of hematological malignancies. In this article, a brief but comprehensive review is ...
Cancer Therapy Advisor - Fri, 31 Jul 2015 06:18

Whole-exome analysis reveals novel somatic genomic alterations associated with ...
Correspondence: Dr AJ Novak, Division of Hematology, Mayo Clinic, 200 1st Street SW, Rochester 55905, MN, USA. E-mail: Novak. ... Although clinical factors such as age, sex, lactate dehydrogenase, extranodal sites, bulky disease, stage, performance ...
Nature.com - Fri, 28 Aug 2015 06:18



Persistent mutations may predict EFS, OS outcomes in AML
"Such information is important to know because high-risk patients need aggressive, potentially curative therapy with a stem-cell transplant when they are in remission, early in the course of the disease,” Levy said. “However, we don't want to ...
Healio - Fri, 28 Aug 2015 14:33

Big data-driven health care research programme in the pipeline
One of the objectives of the proposed hematologic malignancies (HM) project would be to pool information from large and "diverse data sets" and design standards that would allow the data to be used by both health care providers and patients.
Out-Law.com - Fri, 28 Aug 2015 04:03



Spark Therapeutics Downgraded by Zacks (ONCE)
The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based ...
Dakota Financial News - Thu, 27 Aug 2015 16:26

Analysts Set Spark Therapeutics PT at $73.00 (NASDAQ:ONCE)
WKRB News - Sat, 29 Aug 2015 06:52

Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and ...
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel ...
CNNMoney - Thu, 27 Aug 2015 12:52

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Price Target Update
The Companys lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective ...
OTC Outlook - Thu, 27 Aug 2015 20:45


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014